The clinical trial program for cilengitide includes a companion diagnostic biomarker test, PredictMDx for Glioblastoma, produced by MDx Health, which identified the methylation status of the MGMT gene in patients.

The team, led by Shogo Ishiuchi, a teaching assistant at Gunma University's Department of Neurosurgery, examined the role of calcium-permeable glutamate receptors on cells of glioblastoma and found that making them calcium-impermeable inhibited tumor cell migration, according to the study.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.